Utilisation and optimisation of HF guideline‐directed medical therapies (GMDTs) (i.e. renin‐angiotensin system inhibitors (RASIs), HF‐specific beta‐blockers, mineralocorticoid receptor antagonists (MRAs) and, more recently, sodium‐glucose co‐transporter‐2 inhibitors (SGLT2‐i)) have demonstrated reduced mortality and hospitalisation.4 This evidence concerns the gene SLC5A2 and hydrops fetalis.